论文部分内容阅读
目的:探讨术中植入125I放射性粒子辅助治疗老年胸段食管癌的疗效和可行性。方法:老年胸段食管癌患者64例随机分为术中植入125I放射性粒子组(观察组)和术后外放疗组(对照组),比较2组术后1,3年生存率和局部控制率及不良反应发生率。结果:2组不良反应发生率分别为71.9(0/32)及25%(8/32),2组间比较差异有统计学意义(P<0.05);观察组术后1,3年生存率分别为75.0%(24/32),53.1%(17/32),对照组术后1,3年生存率分别为71.9%(23/32),46.9%(15/32),2组比较差异无统计学意义(P>0.05);观察组术后1,3年局部控制率分别为90.6%(29/32),46.9%(15/32),对照组术后1,3年局部控制率分别为68.8%(22/32),34.4%(11/32),观察组优于对照组,2组间比较差异有统计学意义(P<0.05)。结论:术中植入125I不良反应轻,可减少局部复发,缩短治疗周期,但对术后生存率改善不明显,可作为综合治疗方法之一部分代替术后放疗。
Objective: To investigate the efficacy and feasibility of intraoperative implantation of 125I radioactive particles in the treatment of elderly thoracic esophageal cancer. Methods: Sixty-four elderly patients with thoracic esophageal cancer were randomly divided into intraoperative 125I radioactive seed group (observation group) and postoperative external radiotherapy group (control group). The postoperative one and three year survival rate and local control Rate and incidence of adverse reactions. Results: The incidence of adverse reactions in the two groups were 71.9 (0/32) and 25% (8/32), respectively. The difference between the two groups was statistically significant (P <0.05). The 1-year and 3-year survival rates Respectively, 75.0% (24/32) and 53.1% (17/32) respectively. The 1-year and 3-year survival rates of the control group were 71.9% (23/32) and 46.9% (15/32) (P> 0.05). The local control rates in the observation group were 90.6% (29/32) and 46.9% (15/32) respectively at 1 and 3 years after operation, while the local control rates at 1 and 3 years after operation in the control group Respectively, 68.8% (22/32) and 34.4% (11/32) respectively. The observation group was superior to the control group, and the difference between the two groups was statistically significant (P <0.05). Conclusions: Intraoperative 125I with light adverse reactions can reduce the local recurrence and shorten the treatment cycle, but the improvement of postoperative survival rate is not obvious. It can be used as a part of comprehensive treatment instead of postoperative radiotherapy.